March 11, 2026. 12 cannabis news items, curated from live RSS feeds. Sorted by relevance score.
Cannabis study finds THC can create false memories – ScienceDaily
Summary
A study demonstrates that THC can generate false memories, with potential implications for understanding cannabis effects on cognitive function and memory formation in clinical and neuroscientific contexts.
Alabama: Commissioner Says Patients Can Likely Begin Accessing Medical Cannabis … – NORML
Summary
Alabama’s medical cannabis program is advancing toward patient access through licensed dispensaries, while research indicates cannabis use may not impair cognitive function in older adults.
Study suggests CBD and CBG could be treatment for a common chronic liver disease
Research indicates cannabinoids CBD and CBG may treat chronic liver disease, contributing to growing evidence for non-intoxicating cannabinoids’ potential medical applications.
From curiosity to consultation: How patients are learning the basics of medical cannabis care
This article examines how patients are acquiring foundational knowledge about medical cannabis within regulated healthcare frameworks, emphasizing its integration into clinical practice.
The Endocannabinoid System: The Master Regulator of Human Health
Article Summary
This article examines the endocannabinoid system’s regulatory role in human health, linking elevated Omega-6 consumption to ECS dysfunction and discussing medical cannabis as a therapeutic application.
Could President Trump’s marijuana order bring medical cannabis to Tennessee? – News Channel 5
Trump’s marijuana rescheduling initiative may influence Tennessee’s medical cannabis legalization debate, with potential clinical implications for patient access to cannabis-based treatments.
Cannabis Client Alert – Week of January 26, 2026 – Dentons
Clinical Relevance Summary
This article covers regulatory and legal developments in U.S. cannabis markets, including antitrust litigation and state program oversight—relevant to clinical practice regarding product availability, licensing, and patient access.
Two Years of Legal Cannabis: Berlin Police See Surprising Results
Article Overview
This article examines Berlin police enforcement patterns following partial cannabis legalization in 2024, presenting empirical data on law enforcement responses to cannabis consumption.
Patient Protect Supports UK Medical Cannabis Patients Facing Discrimination
Summary
The article discusses Patient Protect’s advocacy efforts addressing discrimination against UK medical cannabis patients and reports on research findings regarding bias in medical cannabis reporting.
Legislation criminalizing excessive marijuana smoke, odor, passed state Senate in bipartisan vote
Article Summary
A state Senate passed bipartisan legislation that criminalizes excessive marijuana smoke and odor emissions, addressing public nuisance concerns in cannabis-legal jurisdictions.
Dr. Corey Herbert shares your health headlines – Instagram
Summary
Dr. Corey Herbert discusses marijuana use among teenagers, citing statistics from a study of 450,000 adolescents aged 13 and older, with implications for youth health outcomes.
President Trump Expected to Sign Executive Order Creating Cannabis Descheduling …
Summary
This article reports on an anticipated executive order by President Trump to deschedule cannabis from federal drug scheduling, with timing tied to midterm elections.
**Clinical relevance:** Descheduling could facilitate increased medical research access and clinical evidence generation for cannabis therapeutic applications.
Clinical Commentary
Clinical Reflection
These items collectively signal that cannabis medicine is transitioning from experimental curiosity to regulated clinical practice, with emerging evidence on specific cannabinoid applications (CBD/CBG for liver disease) alongside important safety data on cognitive effects that should inform patient counseling. Simultaneously, regulatory and legislative momentum, particularly around potential federal descheduling, is creating both opportunities for legitimacy and practical challenges around patient access, discrimination, and standardization that practitioners must navigate. As a clinician, this landscape requires me to ground recommendations in the growing body of evidence while remaining vigilant about cannabinoid-specific risks, particularly regarding memory and adolescent use, and to advocate for patients caught between changing legal frameworks and persistent healthcare stigma.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
